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Abstract 
Background: Programmed cell death 1 (PD-1) receptor-ligand interaction is a major 
pathway often hijacked by tumors in order to suppress immune control. The aim of this 
retrospective study was to investigate the prevalence and prognostic roles of PD-ligand 
1 (PD-L1) expression in small cell lung cancer (SCLC).  
Methods: The expression of PD-L1 was evaluated by immunohistochemical analysis in 
102 specimens of SCLC. Tumors with staining in over 5% of tumor cells were scored as 
positive for PD-L1 expression. Survival analysis was performed using the Kaplan-Meier 
method.  
Results: Expression of PD-L1 in tumor cells was observed in 71.6% (73/102) of 
SCLCs, and was significantly correlated with a limited disease (LD) stage. SCLC 
patients with PD-L1-positive tumors showed significantly longer overall survival (OS) 
than those with PD-L1-negative (median OS, 16.3 versus 7.3 months; p<0.001, 
respectively). Multivariate analyses demonstrated that a good performance status, LD 
stage and expression of PD-L1 were significantly predictive of better OS, independently 
of other factors. We found no relevance between PD-L1 expression and progression-free 
survival for first-line treatment in LD- and extensive disease-SCLC patients.  
Conclusions: In patients with SCLC, expression of PD-L1 is positively correlated with 
a LD stage, and is independently predictive of a favorable outcome.  
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Introduction 
Lung cancer is the leading cause of cancer death worldwide.1 Small cell lung 
cancer (SCLC) is a histological subtype that accounts for approximately 15% of all lung 
cancers cases.2 Systemic chemotherapy is the standard type of care for SCLC. Although 
SCLC shows a good response to initial treatment, most patients suffer disease 
recurrence and become refractory to chemotherapy. Despite intensive research, the 
prognosis of SCLC remains poor, and therefore new strategies to improve outcome are 
urgently needed.  
Blockade of immune checkpoints with monoclonal antibodies has also recently 
emerged as a new therapeutic tool in oncology.3, 4 Programmed cell death 1 (PD1), 
which belongs to the CD28 family of proteins, is a receptor expressed on the surface of 
T cells that regulates their activation and proliferation.3, 4 Its ligand, programmed cell 
death–ligand 1 (PD-L1), is frequently overexpressed in many types of human cancer.5 
Recent clinical trials have indicated that inhibition of this pathway with anti-PD-1/PD-
L1 antibodies exerts a promising antitumor effect against several human malignancies, 
including non-small cell lung cancer (NSCLC), melanoma, and renal cell cancer.6, 7 
Preliminary analysis of these trials suggests that tumor expression of PD-L1 predicts 
response to PD-1/PD-L1 directed therapy. However, the clinical relevance of PD-L1 
expression in SCLC has remained unclear. We therefore examined PD-L1 expression in 
SCLC and analyzed its associated clinicopathologic characteristics and prognostic 
relevance. 
 
Patients and Methods 
Patients 
We retrospectively screened consecutive 178 patients who were diagnosed as 
having SCLC at Kurume University Hospital between 2002 and 2013. Among these 
patients, 108 were histologically diagnosed on the basis of tissue samples obtained by 
biopsy or surgery, and 70 patients were diagnosed by cytological specimens. Adequate 
histological specimens containing abundant tumor cells were available for 102 of these 
patients, who were enrolled in this retrospective study. The tumor specimens were 
derived from primary lung lesion in 83 (81.4%) patients, liver metastasis in four (3.9%), 
brain metastasis in three (2.9%), bone metastasis in two (2.0%), skin metastasis in three 
(2.9%) and lymph node metastasis in seven (6.9%). The clinical characteristics of the 
patients, including age, sex, Eastern Cooperative Oncology Group (ECOG) 
performance status (PS), limited disease (LD)-extensive disease (ED) stage, serum 
lactate dehydrogenase (LDH) level, serum pro-gastrin-releasing peptide (Pro-GRP) 
level, and serum neuron-specific enolase (NSE) level, were recorded. LD stage was 
defined as location of disease within an anatomic region that could be safely 
encompassed within a tolerable radiation field, whereas ED stage was defined as 
extending beyond locoregional boundaries, possibly including malignant pleural or 
pericardial effusion, and hematogenous metastases. The present study was conducted in 
accordance with the provisions of the Declaration of Helsinki and was approved by the 
Institutional Review Board of Kurume University Hospital.  
Immunohistochemical analysis of PD-L1 proteins 
We used 4-μm-thick sections of formalin-fixated, paraffin-embedded tissues. The 
sections were mounted on glass slides and then incubated with anti-rabbit monoclonal 
antibody against PD-L1 (abcam, Cambridge, UK) for immunohistochemical analysis 
with the use of BenchMark XT (Ventana Automated Systems, Inc., Tucson, AZ, USA). 
Briefly, each slide was heat-treated using Ventana’s CC1 retrieval solution for 30 min, 
and incubated with the PD-L1 antibody for 30 min. This automated system used the 
ultraVIEW DAB detection kit with 3, 3' diaminobenzidine (DAB) as the chromogen 
(Ventana Automated Systems). All immunohistochemical analysis was evaluated by two 
experienced observers (A.K. and M.K.) who were unaware of the patients’ conditions. 
Spots for which the pathologists disagreed regarding the staining category were 
reviewed jointly and a single consensus category was established. Cases with less than 
5% tumor staining were considered negative as previous studies.8, 9  
Statistical analyses 
Correlations between PD-L1 expression and patient characteristics were analyzed 
using the chi-squared or Fisher’s exact test for categorical variables. We evaluated 
whether parameters including PD-L1 expression were associated with the survival of 
SCLC patients. Overall survival (OS) was measured from administration of treatment or 
initial diagnosis until the date of death or last follow-up. PFS was defined as the period 
from the date of initiation of first-line treatment to the date of disease progression or 
death due to any cause. The Kaplan-Meier method was used to assess the patients’ 
survival curves and the log-rank test was used to evaluate the significance of differences 
between two groups. Multivariate regression was performed using the Cox proportional 
hazards model. All variables that had p values of <0.05 were included in the Cox model. 
All tests were two-sided, and differences were considered statistically significant at P 
<0.05. All of the statistical analyses were conducted using JMP version 10 (SAS 
Institute Inc., Cary, NC).  
 
Results 
Patient characteristics 
The clinical characteristics of the 102 patients are shown in Table 1. The median 
age of the patients at diagnosis was 70 years (range, 36-85 years). Eighty-nine (87.3%) 
of the patients were male, and 87 (85.3%) patients had a good PS (0-1). Forty-one 
patients (40.2%) had LD and 61 (59.8%) had ED at the time of diagnosis. The median 
LDH level was 245 U/L (range, 138–3476 IU/L). The LDH level was found to be lower 
than or equal to the upper normal limit of 229 IU/L in 37 patients (36.3%), and was 
higher than 229 IU/L in 65 patients (63.7%). The Pro-GRP and NSE serum levels were 
available in 101 (99.0%) and 79 (77.5%) patients, respectively, and the median values 
were 294 pg/mL (range, 12.6-33300 pg/mL) and 22.4 ng/mL (range, 5.2-581 ng/mL), 
respectively. ED-SCLC patients were treated with platinum-based chemotherapy as a 
first line treatment. Among 41 LD-SCLC patients, 31 (75.6%) patients were treated by 
concurrent chemoradiotherapy, three (7.3%) were treated by platinum-based 
chemotherapy, and seven (17.1%) were treated by surgical resection followed by 
platinum-based chemotherapy.  
 
PD-L1 protein expression 
Immunostaining for PD-L1 was observed in the membrane and/or cytoplasm of the 
tumor cells and stromal lymphocytes. Representative PD-L1 staining patterns in the 
tumor specimens are shown in Figure 1. Seventy-three (71.6%) SCLC patients had 
positive tumor PD-L1 staining.  
Correlation between PD-L1 expression and patient characteristics 
The relationship between PD-L1 expression and patient demographics is shown in 
Table 1. Expression of PD-L1 was significantly higher in SCLC patients with LD than 
in those with ED (p=0.011). No significant correlation was observed between PD-L1 
expression and age (p=0.272), sex (p=0.186), PS (p=0.758), serum LDH level 
(p=0.108), serum Pro-GRP level (p=0.609), and serum NSE level (p=0.666).  
Survival analysis 
At the time of analysis, the median duration of follow-up was 11.4 months (range, 
0.7-134.6 months). The PD-L1-positive group showed significantly longer OS than the 
PD-L1-negative group (median 16.3 months versus 7.3 months, p<0.001; Figure 2). 
Univariate analysis revealed that a LD stage (p<0.001), a good PS (p<0.001), a low 
serum NSE level (p<0.001), a normal serum LDH level (p=0.039), and expression of 
PD-L1 (p<0.001) were significantly associated with a favorable OS, whereas none of 
the other factors examined was significantly associated with OS (Table 2). We 
performed multivariate analysis to examine which factors were associated with 
expression of PD-L1. Multivariate analyses demonstrated that a good PS, a LD stage 
and expression of PD-L1 were independent and significant predictive factors for OS 
(Table 3). Sub-analysis of ED-SCLC patients showed that the PD-L1-positive group had 
a longer OS than PD-L1-negative group (median 9.2 months versus 5.4 months, 
p=0.037; Figure 3A), whereas there was no significant difference in PFS between the 
positive and negative groups (median 5.2 months in the positive group versus 4.6 
months in the negative group, p=0.747; Figure 3B). In LD-SCLC patients, there was no 
significant difference in OS (median 25.5 months in the positive group versus 21.8 
months in the negative group, p=0.146; Figure 3C) and PFS (median 10.6 months in the 
positive group versus 7.9 months in the negative group, p=0.083; Figure 3D) between 
the positive and negative groups.  
 
Discussion 
Although blockade of immune checkpoints with monoclonal antibodies has also 
recently emerged as a new therapeutic strategy in several malignancies,3, 4 the 
clinicopathologic characteristics associated with PD-L1 expression in SCLC have 
remained largely unknown. Here, using immunohistochemistry, we examined PD-L1 
expression in 102 specimens of SCLC, and found that expression of PD-L1 in SCLC 
(71.6%) was relatively higher than those of NSCLC 10-12 , and was correlated with a LD 
stage, which also corresponded to the subsets of patients who were more likely to have 
a good outcome.  
Several studies have reported the association between clinicopathologic factors and 
PD-L1 expression in lung cancer.10-12 Some have shown that expression of PD-L1 is 
more correlated with a higher grade of differentiation, while others have found no 
significant correlations.10, 11 Additional work will be needed to clarify why these factors 
are associated with PD-L1 expression.   
We found that patients with expression of PD-L1 had significantly better 
survival than those with negative expression. Multivariate analysis revealed that 
expression of PD-L1, a good PS and a LD stage were significantly associated with 
better prognosis independently of the other factors examined. Given that a LD stage has 
been reported as prognostic factor in SCLC patients, expression of PD-L1 might be 
related to a good prognosis. As far as we are aware, a significant association between 
PD-L1 expression and better prognosis has not previously been demonstrated for 
individuals with SCLC. These results are in line with previous studies showing that 
expression of PD-L1 is associated with better prognosis in patients with NSCLC, 
colorectal cancer, breast cancer, and malignant melanoma.10, 12, 14-17 In contrast to our 
study, several previous studies have reported that expression of PD-L1 protein was 
associated with poor prognosis in patients with NSCLC, esophageal carcinoma, gastric 
carcinoma, hepatocellular carcinoma, pancreatic carcinoma, renal cell carcinoma, and 
ovarian carcinoma.11, 18-26 These conflicting results may be due to a number of reasons. 
One explanation is that determination of PD-L1 expression in tumor samples has 
generally been performed by immunohistochemistry using various antibodies in 
different malignancies. Second, the threshold for positivity has not been clearly defined, 
and reproducibility has not been formally assessed. For future clinical applications, 
further efforts to standardize a quantitative assay for PD-L1 expression are warranted. 
We further analyzed whether PD-L1 expression in tumor cells is correlated with PFS 
in LD- and ED-SCLC. We found no relevance between PD-L1 expression and PFS in 
SCLC, suggesting that PD-L1 expression may be a prognostic factor rather than a factor 
predictive of the response to chemotherapy. Previous studies have shown that PD-L1 
expression is driven by various oncogenic signaling pathways.27-30 Accordingly, we 
speculate that effective chemotherapy may weaken anti-tumor immunity by regulating 
the expression of PD-L1. Additional work will be needed to clarify these issues.  
Our study had a number of limitations. One major weakness was that the number 
of patients studied was relatively small. Secondly, the information was collected 
retrospectively, and thirdly, PD-L1 expression was evaluated from formalin-fixed 
paraffin-embedded specimens obtained by trans-bronchial lung biopsy (TBLB) in most 
cases. Although most SCLC patients are diagnosed at a late disease stage, surgically 
resected samples containing an adequate number of tumor cells are not obtained in 
clinical practice. 
 In conclusion, we have demonstrated that expression of PD-L1 was present in 
over 70% of SCLC patients and was associated with a better prognosis. Further studies 
are warranted to clarify the role of PD-L1 expression, and the therapeutic effect of PD-
1/PD-L1 blockade, in SCLC models and clinical trials. These data provide a basis for 
implementation of cancer immunotherapy in patients with SCLC. 
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Figure legends 
Figure 1. Positive programmed cell death-ligand 1 (PD-L1) immunohistochemical 
staining pattern (A) and negative immunohistochemical staining pattern (B).  
 
Figure 2. Kaplan-Meier overall survival curves for SCLC patients with positive and 
negative expression of PD-L1.  
 
Figure 3. Kaplan-Meier curves for overall survival (OS) (A) and progression-free 
survival (PFS) (B) of ED-SCLC patients with high or low expression of PD-L1. 
Kaplan-Meier curves for overall survival (OS) (C) and progression-free survival (PFS) 
(D) of LD-SCLC patients with high or low expression of PD-L1 
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Table 1. Patient characteristics and their association with PD-L1 expression. 
Variables No. of patients   PD-L1 expression     p-value 
      Positive Negative     
Age       
  <70 51  39 12  0.272  
  ≥70 51  34 17   
Sex       
  Male 89  66 23  0.186  
  Female 13  7 6   
Performance status       
  0-1 87  63 24  0.758  
  2-3 15  10 5   
Stage       
  LD 41  35 6  0.011  
  ED 61  38 23   
Serum LDH level       
  Normal 37  30 7  0.108  
  Abnormal 65  43 22   
Serum Pro-GRP level       
  Median 294  304 265  0.609  
  Range 12.6-33300  13.8-31400 12.6-33300   
Serum NSE level       
  Median 22.4  19.6 26.7  0.666  
  Range 5.2-581   5.2-581 5.6-309     
Abbreviations: PD-L1, programmed cell death-ligand 1; LDH, lactate dehydrogenase; 
Pro-GRP, pro-gastrin-releasing peptide; NSE, neuron-specific enolase.  
 
 
 
 
Table 2. Univariate analysis of prognostic factors for overall survival.  
Factor Number Median OS (mo) HR (95% CI) p-value 
Age     
  <70 51 14.6  1.161 (0.755-1.778) 0.492 
  ≥70 51 11.9    
Sex     
  Male 89 13.2  0.908 (0.512-1.761) 0.756 
  Female 13 17.6    
Performance status     
  0-1 87 15.2  0.227 (0.131-0.419) <0.001 
  2-3 15 1.9    
Stage     
  Limited disease 41 25.5  0.254 (0.154-0.408) <0.001 
  Extensive disease 61 8.4    
Serum LDH level     
  Normal  37 18.3  0.628 (0.398-0.974) 0.039 
  Abnormal 65 9.7    
Serum Pro-GRP level     
  Low (< median) 50 14.5  0.682 (0.440-1.054) 0.104 
  High (> median) 51 12.9    
Serum NSE level     
  Low (< median) 39 18.0  0.433 (0.259-0.718) <0.001 
  High (> median) 40 9.5    
PD-L1 expression     
  Positive 73 16.3  0.408 (0.257-0.664) <0.001 
  Negative 29 7.3      
Abbreviations: OS, overall survival; HR, hazard ratio; CI, confidence interval; LDH, 
lactate dehydrogenase; Pro-GRP, pro-gastrin-releasing peptide; NSE, neuron-specific 
enolase; PD-L1, programmed cell death-ligand 1.  
 
 
Table 3. Multivariate analysis of factors for overall survival.  
Factor Hazard ratio 95% CI p-value 
PS (0-1/2-3) 0.390  0.192-0.841 0.018  
Stage (LD/ED) 0.403  0.199-0.804 0.010  
NSE level (Low/High) 0.671  0.358-1.225 0.196  
LDH level (Normal/Abnormal) 1.130  0.628-1.995 0.679  
PD-L1 expression (Positive/Negative) 0.435  0.241-0.803 0.008  
Abbreviations: CI, confidence interval; PS, performance status; LD, limited disease; 
ED, extensive disease; LDH, lactate dehydrogenase; NSE, neuron-specific enolase; PD-
L1, programmed cell death-ligand 1.  
 
